Endpoints News 23. März 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
FierceBiotech 23. März 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech 20. März 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Endpoints News 20. März 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 26. Feb. 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 20. Feb. 2026 Novartis to divest India unit to private equity-led consortium for $159M
FierceBiotech 18. Feb. 2026 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Endpoints News 18. Feb. 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News 18. Feb. 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
FierceBiotech 4. Feb. 2026 Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates